ストックスクリーナーアプリを入手
2.60
0.78%
0.02
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders - Quantisnow
AIM ImmunoTech Announces CEO Corner Segment Release - AInvest
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewswire
Biotech AIM ImmunoTech's CEO Details Progress of Promising Pancreatic Cancer Drug Ampligen in Latest Update - Stock Titan
AIM ImmunoTech's Oncology Gambit: Can Pancreatic Cancer Breakthroughs and Financial Stability Fuel a Biotech Comeback? - AInvest
AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year - MSN
AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k. - AInvest
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Promising Pancreatic Cancer Treatment: AIM ImmunoTech's Ampligen Shows Strong Safety Data in Phase 2 - Stock Titan
Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest
AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials - TipRanks
AIM ImmunoTech to present at Webull Financial Corporate Connect webinar. - AInvest
AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire
AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. - AInvest
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - The Manila Times
AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan
AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest
AIM ImmunoTech Closes $8 Million Public Offering - The Globe and Mail
Latest News - Asia Food Journal
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech closes public offering, raises $8 mln. - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Stock Dives 50% After Priced Public Offering - AInvest
Why Is AIM ImmunoTech Stock (AIM) Down 50% Today? - TipRanks
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Announces $8 Million Public Offering at $4 per Share with Accompanying Warrants. - AInvest
AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest
0.24%
8.71%
大文字化:
|
ボリューム (24 時間):